According to FutureWise analysis the market for lentiviral vector in 2023 is US$ 176.8 million, and is expected to reach US$ 690 million by 2031 at a CAGR of 17.6%.
Lentiviral vectors (LV) are effective vehicles for gene transfer in mammalian cells due to their ability to stably express a gene of interest in both non-dividing and dividing cells. Pathogens known as lentiviruses affect both humans and animals and have protracted incubation times. The interval between the first infection and the onset of the first symptoms can be many months or even several years. To introduce genetic material into cells, molecular scientists typically use viral vectors. The operation can be carried out (in vitro) as well as In vivo (within a living creature) or in cell culture. For effective genome transfer inside the infected cells, viruses have developed specialised molecular pathways.
Over the past two decades, lentiviral vectors, which are derived from the human immunodeficiency virus, have been thoroughly studied and improved. Recent clinical trials have used third-generation, self-inactivating lentiviral vectors to insert genes into hematopoietic stem cells to treat primary immunodeficiencies and hemoglobinopathies. The development of gene-modified cell therapies, particularly T-cell therapies, has been greatly aided by lentiviral vectors. Examples of T cell treatments that are currently commercially accessible for distribution after successfully getting EMA and FDA authorisation for the treatment of blood malignancies include tisagenlecleucel (Kymriah), axicabtagene ciloleucel (Yescarta) and, most recently brexucabtagene autoleucel (Tecartus). The therapeutic chimeric antigen receptor (CAR) is transduced into T cells in all three treatments using retroviral vectors.
FutureWise Market Research has published a report that provides an insightful analysis of lentiviral vector market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry.
According to the analysis conducted by FutureWise research analysts, the lentiviral vector market is estimated to register a considerable growth rate over the forecast period. This report lists the market segments and potential prospects available across this industry, in addition providing crucial information on the total valuation currently held by the industry. Moreover, this report will assist key management individuals in an organisation to enhance their decisions pertaining to business expansion as well as strategic changes for increasing customer base.
Lentiviral vectors have already aided gene-modified cell-based therapeutics, particularly T cell therapies. Such vectors are also used to deliver cloned T-cell receptors or chimeric antigen receptors to mature T cells to trigger anti-cancer immunity (CARs). The FDA approved the first genetically altered cellular therapy in response to the astounding clinical success of CAR T-cell therapies created with lentiviral vectors in patients with B-cell malignancies. Due to its usage in the creation of COVID-19 vaccines, lentiviral vectors have seen an upsurge in demand in recent years. As a result, the market will rise due to the widespread usage of lentiviral vectors in the creation of numerous vaccines. Understanding of lentivirus biology has aided in the creation of lentiviral delivery vectors for medical applications. Lentiviral vectors are thus one of the most efficient ways to deliver genes. They are often employed for both fundamental biological research and medical applications due to their unique properties. However, costs associated with gene therapy is the main problem. Drug prices are typically regulated and guided by existing legislation in many countries, but the cost of gene therapy is mostly unregulated and set on an individual basis, with an emphasis on a single upfront payment. Lentiviral vector sales may be impacted by the limited number of businesses creating gene therapies for rare diseases and the small number of patients who can benefit from these medicines.